登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《EClinicalMedicine，6月20日，Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-21

  • Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
    Author links open overlay panelTariqKewana1FahrettinCovuta1Mohammed J.Al–JaghbeerbLoriRosecK.V.GopalakrishnadBasselAkbikb
    Show more
    https://doi.org/10.1016/j.eclinm.2020.100418

    Abstract
    Background
    Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients.

    Methods
    In this retrospective cohort study, we analyzed hypoxic COVID–19 patients who were consecutively admitted between March 13, 2020 and April 19, 2020. Patients with lung infiltrates and elevated inflammatory markers received a single dose of tocilizumab if no contraindication was present. Systemic steroid, hydroxychloroquine, and azithromycin were concomitantly used for majority of the patients.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S2589537020301620
159浏览量
原文链接
相关报告

  • 《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-26
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study Prof Giovanni Guaraldi, MD † Marianna Meschiari, MD † Prof Alessandro Cozzi-Lepri, PhD Jovana Milic, MD Roberto Tonelli, MD Marianna Menozzi, MD Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9 Summary Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.
    186浏览量
    原文链接

  • 《PNAS，4月29日，Effective treatment of severe COVID-19 patients with tocilizumab》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-01
    • Effective treatment of severe COVID-19 patients with tocilizumab Xiaoling Xu, View ORCID ProfileMingfeng Han, Tiantian Li, Wei Sun, View ORCID ProfileDongsheng Wang, Binqing Fu, Yonggang Zhou, Xiaohu Zheng, View ORCID ProfileYun Yang, Xiuyong Li, Xiaohua Zhang, Aijun Pan, and Haiming Wei PNAS first published April 29, 2020 https://doi.org/10.1073/pnas.2005615117 Edited by Zhu Chen, Shanghai Jiao Tong University, Shanghai, China, and approved April 14, 2020 (received for review March 25, 2020) Abstract After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 ± 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
    132浏览量
    原文链接